This study investigates the proliferative and osteogenic role of marrow stromal/osteoprogenitor cells in the development of the cortical bone deficit in ovariectomized (OVX) female rats. In vitro, clonal growth of marrow stromal cells from OVX rats was significantly impaired (vs. sham-operated controls). Yet in vivo, cells from sham-operated and OVX rats had equal osteogenic potential in several in vivo experimental situations, such as in intraperitoneally implanted millipore diffusion chambers and in intramuscular implants of marrow plus osteoinductive bone matrix (composite grafts). Long-term (6 mo) dihydrotachysterol (DHT) treatment of OVX rats enhanced their in vitro proliferative potential and clonal growth, as well as their osteogenic expression in composite grafts. The observation that the in vivo osteogenic performance of OVX rat marrow stromal cells was normal at extraosseous sites suggests that the mechanisms leading to osteopenia may involve an abnormality in cell-matrix interactions.
Introduction
It is well known that rats develop osteopenia after ovariectomy (OVX),' and the OVX rat has been used as a model for postmenopausal osteoporosis (1) (2) (3) . Our studies have shown that bone density in rats is reduced 6 mo post-OVX, and that the ratio of femoral cortical thickness to midshaft diameter was significantly lower than normal (x-ray femoral score; Table I ). This suggested that the osteopenia might be due in part to deficient endosteal bone formation, and, by extension, either to a deficit in the proliferative capacity of osteoprogenitor cells (OPC) and/ or to their capacity to modulate to functional osteoblasts. Marrow might serve as the source of the OPCs for endosteal osteoblasts since the stromal cells within marrow grafts form bone in ex-matrix; DHT, dihydrotachysterol; FCFU, fibroblast colony forming units; OPC, osteoprogenitor cells; OVX, ovariectomy (ovariectomized); PE, FCFUJ plating efficiency. traosseous sites (4) , within millipore diffusion chambers (5) , and in culture (6) . In vitro, marrow stromal cells form clones known as fibroblast colony forming units (FCFU) (7) , and, in rats, the FCFU census appears to be closely associated with the in vivo osteogenic performance of marrow biopsies combined with osteoinductive demineralized bone matrices (8) . If the in vitro FCFU census could be used as an indirect osteogenic bioassay, and it might prove to be a system which could be applied in animal model systems and patients to develop a fuller understanding of mechanisms involved in the development of the osteoporoses.
In this study, we focus on the relationships between the in vivo patterns of FCFU development from, and proliferation kinetics of isolated marrow cell preparations derived from, agematched intact and OVX rats, and the in vivo capacities ofthese cells to form bone in several animal model systems. We also tested the effect of protracted oral administration of dihydrotachysterol, a 1,25(OH)2D3 analogue, on these parameters since vitamin D therapy has resulted in improved calcium balance and bone mass/density scores in OVX rats (9, 10) and postmenopausal osteoporotic women (11) (12) (13) (14) . The data indicate that the cortical bone deficit in OVX rat is associated with an impaired proliferative capacity of marrow stromal osteoprogenitor cells rather than with the inability ofthese cells to differentiate/mature into functional osteoblasts. Dihydrotachysterol treatment improved FCFU proliferation as well as their osteogenic potential in demineralized bone-marrow composite grafts.
Methods

Animals
Female rats (Sprague-Dawley strain, 50-60 d old, 200 g body weight) were surgically ovariectomized (OVX), and they and their age-matched intact controls were maintained in a vivarium under conditions of ad lib. feeding (Purina Lab Chow; Ralston Purina Co., St. Louis, MO). Tap water was freely available. The OVX rats were significantly heavier (20%) than their age-matched intact controls at 1.5 mo postoperatively when, in several studies, OVX animals began to be treated for 1, 3.5, or 6 mo with dihydrotachysterol (1.0 or 2.0 Ag/100 g body weight, three times per week; (Table I) . 6 mo postoperatively, the femurs from untreated rats also demonstrated thinner than normal cortices and they were undermineralized (ash weight and bone density; Table I ). (Fig. 1 ). The differences in growth were highly reproducible and were apparent as early as the seventh day of culture (Fig. 2) were similar in terms of their size distributions (control, 1.65±0.19 mm2 OVX, 1.47±0.87 mm2) and in the proportion of clones that were alkaline phosphatase-positive (7 
Cell proliferation studies
The fractional retention of 3H-activity was significantly greater in the cultures of cells harvested from the control animals than from OVX rats (Fig. 3) . Differences in cell proliferation were evident by the seventh day ofculture. The activity incorporated by the cells in control cultures was four to five times that of the OVX cultures by the 12th day. Table II shows that in three offour experiments, marrow cultures from 5-9-mo-old OVX rats that had been treated with 1.0 and 2 ,.g, respectively, for 1 or 6 mo postoperatively grew a significantly greater number of FCFU than marrow from untreated OVX rats (P < 0.05-<0.00 1). At the lower dose level and short treatment time, the DHT-FCFU census was slightly lower than that observed in cultures of marrow from untreated sham-operative rats. At the higher dose with the longer treatment time, DHT markedly increased the FCFU census above the values recorded for the sham-operative and untreated OVX rats (P < 0.01). The benefit of DHT treatment was not observed in a single experiment of 3.5-mo duration.
Effect ofdihydrotachysterol treatment on marrow cells in vitro
In vivo animal models Millipore diffusion chambers. The radioactivity incorporated into the contents of the diffusion chambers varied over a wide range mized female rats. in each group (cpm, <100-> 15,000). ANOVA indicated that the osteogenic performance of the stromal cells derived from marrows of sham-operative and OVX rats were not statistically different in the different types of host rats. However, rank-order analyses (Mann-Whitney U Test) indicated that the stromal cells from OVX rats formed significantly more bone in sham-operative hosts than in OVX hosts, but that OVX-stromal cells did not outperform the sham-operative stromal cells in the shamoperative hosts (Table III) .
Composite bone grafts (Table IV) . Radiocalcium incorporation by composite grafts ofallogeneic bone-autologous marrow was not quantitatively different 2-3 wk after intramuscular implantation, irrespective of the ages of the rats from which the marrow was obtained. However, isotope incorporation was markedly increased two-to threefold in the grafts implanted in 20 wk post-OVX DHT-treated rats.
Demineralized allogeneic bone implants (Table IV) The patterns of radiocalcium incorporation by DBM grafts in sham-operative and OVX rats mirrored the results observed for the composite bone grafts. Isotope retention was nearly identical in DBM grafts implanted in sham-operative and OVX hosts, but it was significantly increased after DHT treatment. In the same animal, DBM grafts always incorporated two-to threefold less "5Ca than the marrow-replete composite grafts (P < 0.01).
Endosteal boneformation/mineralization
The radiologic bone score measurements for ovariectomized (OVX) rats 6.0 mo postoperatively were significantly lower than normal (Table I) . Ultraviolet microscopy of diaphyseal bone sections from the femurs of sham-operative, OVX and 6-mo DHT-treated OVX rats revealed double tetracycline labels on periosteal surfaces, and only single labels on endosteal surfaces. The rate of periosteal appositional bone growth/mineralization in these very mature rats was in the order of 1.0 ,um/d.
Discussion
It has long been recognized that marrow stromal cells have osteogenic potential (5, 7, 8) , but there has been no direct evidence, in lieu of pathology or of fracture healing, that they ever express this potential in situ. We attempted to develop such data using 14.2±0.9 (6) 33.7±3.7 (6) 9 7 OVX -2.9±0.6 (6)1 7.0±0.6 (6) ovx.
the OVX rat as an osteopenic model. The experiments were designed to explore the possibility that the thinning of diaphyseal bone cortices in rats after ovariectomy was due, at least in part, to a deficit in the proliferation and/or the osteogenic expression of the putative endosteal osteoprogenitor marrow stromal cell population. This validity of the thesis was tested by comparing the growth of marrow stromal cells in vitro to their ability to sustain osteogenesis in different kinds of bone grafts in vivo.
Parallel studies were conducted in OVX rats treated in vivo with DHT; these studies were predicated upon reports that DHT and the active vitamin D metabolite, 1,25(OH)2D3, are structurally similar and have stereospecific receptors on bone cells (17 (15, 21) . From the standpoint ofcell-matrix interactions, the apparently normal performance of these cells in vivo at sites away from bone suggests that OVX rat matrix could be deficient in one or more of the noncollagenous proteins that constitute the biologically active BMP (21, 22) . Other mechanisms such as immunologically based cellular interactions or "systemic changes" in endocrine sensitivity of bone cells (e.g., parathyroid hormone) could also be involved, but ifpresent, these are probably oflesser importance (23) . Here, cells removed from the constraint of a hypothetically unfavorable local intraosseous microenvironment rapidly recovered and proved superior to cells biopsied from normal rats in their ability to proliferate and mature (viz Millipore Diffusion Chambers); the outcome resembled a catch-up growth phenomenon (24) (25) (26) . Vitamin D metabolites and analogues may operate at these different levels in bone. However, when our findings that DHT treatment enhanced the osteoinductive potential of allogeneic DBM are viewed from the perspective ofthe recent work by Canalis (27) , it would appear that the primacy of DHT action was to stimulate osteoprogenitor cell proliferation. In this particular experimental model, the secondary consequences of DHT treatment would be expressed as enhanced osteoblast maturation and new bone formation (28) .
In other situations such as in osteoblast cultures, 1,25(OH)2D3 treatment appears to enhance those activities or processes that denote cell maturation/differentiation (alkaline phosphatase and collagen synthesis), and has no effect on cell proliferation (28) . We conclude that the bone mass deficit which develops in rats after ovariectomy can be corrected by oral DHT administration, and that the mechanism of hormone action involves a primary stimulus to mesenchymal osteoprogenitor cell proliferation (endosteal marrow stromal cells and periosteum).
